Last one with reference links I read through trying to get up to...

Last one with reference links I read through trying to get up to speed & join dots for anyone interested or not been through them. Obviously have a leaning towards a positive near term outcome personally. We'll see. GLA

With regards to the Agila Patent, this has cited POH prev patents but appears cited by the examiner.

https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150701&DB=&locale=en_EP&CC=EP&NR=2887953A2&KC=A2&ND=4

https://register.epo.org/application?number=EP13838871&lng=en&tab=doclist

https://patents.google.com/patent/EP3287138A1/en

https://patents.google.com/patent/EP2887953A4/en

https://patents.google.com/patent/WO2011094814A1/en

Original court report & filing for Cubist v Strides / Agila

https://www.patentdocs.org/2013/10/court-1.html

https://patentdocs.typepad.com/files/cubist-v-strides.pdf

Some info on Mylans ANDA 205037

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205037

https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=205037

Mercks own little "Daptomycin: a comparison of two intravenous formulations"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030942/

Extract from Mylan last qtrly which indicates they will hit up Strides possibly as a recourse under their Agila acquisition doc if the Award goes against them. Next qtrly due early next week US time.

http://investor.mylan.com/static-files/09b7ff7a-c583-46a0-b95b-7110ca8a0431

Other CommitmentsThe Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings andlitigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civilpenalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. The Company isalso party to certain proceedings and litigation matters for which it may be entitled to indemnification under the respective sale and purchase agreementsrelating to the acquisitions of the former Merck Generics business, Agila Specialties Private Limited, the EPD Business, and certain other acquisitions. Wehave approximately $58 million accrued for legal contingencies at June 30, 2018.While the Company believes that it has meritorious defenses with respect to the claims asserted against it and intends to vigorously defend itsposition, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict theultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters or the inability or denial of Merck KGaA,Strides Arcolab Limited, Abbott Laboratories, or another indemnitor or insurer to pay an indemnified claim, could have a material adverse effect on theCompany’s business, financial condition, results of operations, cash flows and/or ordinary share price.

Original Mylan Agila Acquisition doc. Was looking for info on existing Licensing or Partner agreements and how treated in the buy out.

Mylan - Agila Acquisition Contract 2013.pdf